Intellia's Lonvo-z cuts HAE attack rate 81% versus prior prophylaxis in phase 3 trial
NTLA•Intellia Therapeutics said Phase 3 HAELO results showed Lonvo-z cut hereditary angioedema attack rates by 81% versus prior preventive treatment, with improved quality of life versus placebo.
1. Phase 3 results
Intellia Therapeutics announced additional positive results for Lonvo-z in hereditary angioedema, with HAELO trial results showing an 81% lower attack rate versus prior preventive treatment and improved quality of life versus placebo. The company plans to present the results at ACAAI on November 13-14, 2026.
2. Follow-up and plans
Intellia said all treated patients across Phase 1/2 and HAELO were free of long-term preventive therapy at their latest follow-up. Follow-up extending to four years showed sustained benefit, with no new long-term safety risks identified, and preparations are underway for a planned commercial launch.
